A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG‑C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors

  • Body, Amy (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date7/11/24 → 6/11/29